Background: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors.
Direct oral anticoagulants are associated with lower rates of bleeding than vitamin K antagonists, but life-threatening bleeding still occurs. Andexanet alfa is a catalytically inactive recombinant modified human factor Xa molecule that...
Introduction: Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. Since May 2018, the FDA has approved its utilization in patients treated with apixaban and rivaroxaban in case of life-threatening or uncontrolled bleeding.
Read the latest publication digest "Managing bleeds related to oral factor Xa inhibitors with andexanet alfa or replacement agents".
One obstacle for the more widespread use of the DOACs in clinical practice has been the lack of a reversal agent. Most DOACs act by directly binding to and inhibiting the effects of factor Xa.
Portola Pharmaceuticals has announced that its first Phase III study of andexanet alfa, a potential universal Factor Xa inhibitor antidote...
Portola Pharmaceuticals announced completion of the submission of a Biologics License Application (BLA) to the FDA for its investigational agent...
Portola Pharmaceuticals announced topline results from the first part of the Phase III ANNEXA-R (Andexanet Alfa a Novel Antidote to...
Portola Pharmaceuticals, Bristol-Myers Squibb and Pfizer Inc. announced full results from the second part of the Phase III ANNEXA-A (Andexanet...
Portola Pharmaceuticals Inc.announced interim results from the ongoing Phase IIIb/IV ANNEXA-4 study of AndexXa (andexanet alfa), a Factor Xa inhibitor...